

Specialty Pharmacy Program

Kineret® (anakinra)

DESCRIPTION

Kineret, an interleukin-1 (IL-1) receptor antagonist, is indicated for the reduction in signs and symptoms and slowing the progression of structural damage in moderately to severely active rheumatoid arthritis (RA) in patients 18 years of age or older who have failed one or more disease modifying antirheumatic drugs (DMARDs).

APPROVAL DURATION

Approval duration: lifetime

APPROVAL CRITERIA

- I. Patients must be 18 years of age or older; AND
- II. Patient must have diagnosis of moderate to severe active rheumatoid arthritis (RA); AND
- III. Patient has had an inadequate response to one or more nonbiologic disease modifying anti-rheumatic agents (DMARDs), or such therapy is contraindicated or not tolerated:
 - A. Auranofin (Ridaura)
 - B. Azathioprine (Imuran)
 - C. Cyclophosphamide (Cytoxan or Neosar)
 - D. Cyclosporine (Neoral or Sandimmune)
 - E. Gold sodium thiomalate (Myochrysine)
 - F. Hydroxychloroquine (Plaquenil)
 - G. Leflunomide (Arava)
 - H. Methotrexate
 - I. Minocycline (Minocin or Dynacin)
 - J. Penicillamine (Cuprimine, Depen)
 - K. Sulfasalazine (Azulfidine, Azulfidine EN-tabs)
- IV. Patient has had an inadequate response to Enbrel (etanercept), Humira (adalimumab), or Remicade (infliximab), or such therapy is contraindicated or not tolerated.
- V. Patient will not use Kineret in combination with a tumor necrosis factor blocking agent or Orencia (abatacept).